The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
C | Cardiovascular system | |
2
|
C08 | Calcium channel blockers | |
3
|
C08C | Selective calcium channel blockers with mainly vascular effects | |
4
|
C08CA | Dihydropyridine derivatives | |
5
|
C08CA05 | Nifedipine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 30 mg | |
| PAREN | Parenteral | 30 mg |
| Active Ingredient |
|---|
|
Nifedipine is a calcium antagonist of the 1,4-dihydropyridine type. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell. As a specific and potent calcium antagonist, nifedipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. The main action of nifedipine is to relax arterial smooth muscle, both in the coronary and peripheral circulation. Nifedipine Tablets are formulated to achieve controlled delivery of nifedipine in a release profile sufficient to enable once-daily administration to be effective in clinical use. |
| Document | Type | Information Source | |
|---|---|---|---|
| ADALAT Tablet | MPI, EU: SmPC | Medicines and Medical Devices Safety Authority (NZ) | |
| FENAMON SR Modified release tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| NIDEF Prolonged release tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| NIFELAT Film-coated tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| PROCARDIA Capsule | MPI, US: SPL/Old | FDA, National Drug Code (US) | |
| PROCARDIA XL Extended release tablet | MPI, US: SPL/Old | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.